Premium
Patient outcomes and amotosalen/ UVA ‐treated platelet utilization in massively transfused patients
Author(s) -
Nussbaumer W.,
Amato M.,
Schennach H.,
Astl M.,
Chen C. Y.,
Lin J.S.,
Corash L.,
Benjamin R. J.
Publication year - 2017
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12489
Subject(s) - medicine , blood product , platelet , hematology , retrospective cohort study , demographics , platelet transfusion , blood transfusion , surgery , demography , sociology
Background Amotosalen/ UVA ‐treated platelet concentrates ( PC s) have demonstrated efficacy for treating and preventing bleeding in clinical trials and in routine use; however, most studies were performed in haematology/oncology patients. We investigated efficacy during massive transfusion ( MT ) in general hospitalized patients. Methods Universal amotosalen/ UVA treatment ( INTERCEPT Blood System) of platelets was introduced at a large Austrian medical centre. We performed a retrospective cohort analysis comparing component use, in‐hospital mortality and length of stay after MT that included platelet transfusion, for two periods (21 months each) before and after implementation. Results A total of 306 patients had MT . Patients were mostly male (74%) and ≥18 years old (99%), including 93 liver transplant, 97 cardiac or vascular surgery and 51 trauma patients. There were no differences in demographics between the periods. Component use on the day and within 7 days of the MT event was unchanged post‐ IBS implementation, except trauma patients received fewer RBC s on the day. The mean ratio of RBC :platelets:plasma on the day of the MT was close to 1:1:1 in both periods, except for liver transplants with MT who received more plasma components. Overall, in‐hospital mortality (preimplementation = 27·6% vs. postimplementation = 24·0%; P = 0·51) and median time to discharge (preimplementation = 27 vs. postimplementation = 23 days; P = 0·37) did not change, except for cardiac and vascular surgery patients who were discharged earlier. Conclusion The introduction of amotosalen/ UVA ‐treated, pathogen‐reduced PC did not adversely affect clinical outcomes in massively transfused patients in terms of blood product usage, in‐hospital mortality and length of stay for a range of clinical indications for platelet transfusion support.